Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression.

Grigolon, Ruth Bartelli; Trevizol, Alisson Paulino; Gerchman, Fernando; Bambokian, Alexander; Magee, Taylor; McIntyre, Roger S.; Gomes, Fabiano A.; Brietzke, Elisa; Mansur, Rodrigo B.

doi:10.1016/j.jad.2021.03.032

Cited by 24 publications

(15 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we found that patients receiving these interventions benefited from body mass index reduction. Obesity is common in patients with major depression and may influence psychiatric trajectory [31,32]. Intentional weight loss improves the symptoms of depression [10].…”

Section: Discussionmentioning

confidence: 99%

Fasting Interventions for Stress, Anxiety and Depressive Symptoms: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Background. Fasting interventions have shown effectiveness in alleviating stress, anxiety and depressive symptoms. However, no quantitative analysis has been carried out thus far. The objective was to determine the effectiveness of fasting interventions on stress, anxiety and depression and if these interventions were associated with increased or decreased fatigue/energy. Methods. Overall, 11 studies and 1436 participants were included in the quantitative analyses. Results. After limiting analyses to randomized controlled trials with low risk of bias, we found that fasting groups had lower anxiety (b = −0.508, p = 0.038), depression levels (b= −0.281, p = 0.012) and body mass index compared to controls without increased fatigue. There was no publication bias and no heterogeneity for these results. These interventions were safe, even in patients with type 2 diabetes. Conclusions. These results should be taken with a caveat. These results are preliminary and encouraging and fasting appears to be a safe intervention. Data are not sufficient to recommend one fasting intervention more than the others. No study was carried out in psychiatric populations and further trials should be carried out in these populations that may be good candidates for fasting interventions.

show abstract

Section: Discussionmentioning

confidence: 99%

Fasting Interventions for Stress, Anxiety and Depressive Symptoms: A Systematic Review and Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Importantly, these analyses highlight the interaction of BMI with the potential of a biomarker effect. The relationship between BMI and increased psychiatric symptoms, including MDD, is well known [ 17 – 19 ]; however, BMI is not frequently included as a variable by which treatment effects are evaluated. Simply controlling for this variability in the model may hide key biological differences in these responses.…”

Section: Discussionmentioning

confidence: 99%

Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory

et al. 2022

View full text Add to dashboard Cite

Fibroblast growth factor 21 (FGF21) is a key regulator of metabolic function and nutrient preference. It also affects biological pathways associated with major depressive disorder (MDD), including corticotrophin-releasing hormone (CRH), leptin, and sympathetic activity. Lower levels of cerebrospinal fluid FGF21 have been associated with higher Beck Depression Inventory scores. FGF21 was examined as a metabolic marker that could be associated with MDD and evaluated as a biomarker of antidepressant treatment response in a large, randomized placebo-controlled trial in chronic, early-onset MDD participants. FGF21 levels at baseline and during treatment were determined for participants in the Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care (EMBARC) study. FGF21 was analyzed by ELISA in individuals with chronic, early-onset MDD (first major depressive episode before 30 years) compared to healthy control participants. Participants with MDD had higher levels of FGF21 compared to healthy controls (HCs), even after controlling for baseline age, sex, race, Hispanic ethnicity, BMI, and site (β-coefficient = 1.20, p < 0.0001, Cohen’s d = 0.60). FGF21 did not change over time nor differ between treatment groups. Interestingly though, those with normal BMI and lower FGF21 levels showed a reduction in depression severity over time compared to all other groups. In conclusion, depression is associated with higher levels of FGF21 compared to healthy controls and those with lower levels of FGF21 (25th percentile of the sample) in the context of normal-weight BMI seem to have improved depression severity over time.

show abstract

“…The benefit on weight was also interpreted as relevant since overweight and obesity are common among patients with depressive and anxiety states [28], and this comorbid condition is related to poor therapy response. [29]. The treatments meta-analyzed by Berthelot also showed to be safe in patients with other comorbid physical conditions, including type-2 diabetes.…”

Section: Diet Intervention On Anxiety and Depressionmentioning

confidence: 98%

Role of Nutrition and Diet on Healthy Mental State

Granero

2022

Nutrients

View full text Add to dashboard Cite

show abstract

Is Obesity A Determinant Of Success With Pharmacological Treatment For Depression? A Systematic Review, Meta-Analysis And Meta-Regression.

Cited by 24 publications

References 73 publications

Fasting Interventions for Stress, Anxiety and Depressive Symptoms: A Systematic Review and Meta-Analysis

Fasting Interventions for Stress, Anxiety and Depressive Symptoms: A Systematic Review and Meta-Analysis

Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory

Role of Nutrition and Diet on Healthy Mental State

Contact Info

Product

Resources

About